Adagio medical reports second quarter 2025 results

Laguna hills, calif.--(business wire)--adagio medical holdings, inc. (nasdaq: adgm) (“adagio” or “the company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the second quarter ended june 30, 2025. recent business highlights: surpassed 85% enrollment in the fulcrum-vt pivotal study of the company's vclas™ cryoablation system. the study, which seeks to enroll 206 patients with either ischemic or non-ischemic.
ADGM Ratings Summary
ADGM Quant Ranking